â??A open clinical trial to evaluate the efficacy of Kuka cough lozenges variants in the patient suffering with Kasa (Acute cough and throat irritation).â??

Multani Pharmaceuticals Ltd0 个研究点目标入组 120 人开始时间: 待定最近更新: 2023年1月9日

试验速览

暂无简介。

•1. Males and females with a history of acute cough due to any cause except those listed in exclusion criteria.
•2. Throat irritation for <1 week duration, who will be able to comply with the study requirements
•3. Patients having a cough score of 0, 1 or 2 during day time (as per Day Time Cough Scale described under end points)
•4. Patients willing and able to provide signed ICF prior to study

•1. Participants with a history of acute lower respiratory tract infections such as pneumonia, bronchitis whooping cough, chronic obstructive pulmonary disease/asthma, tuberculosis, systemic bacterial infections for which specific drug therapy will be required;
•2. Any underlying lung pathology such as lung abscess or cystic fibrosis
•3. Individuals with a history of myocardial infarction within 4 weeks prior to enrollment;
•4. Individuals with a history of Parkinsonâ??s disease and who were on monoamine oxidase inhibitors.
•5. Individuals with any psychiatric illness which may impair the ability to provide written ICF.
•6. Individuals participating in any other clinical trial.
•7. Pregnant or lactating females.
•8. Those who are under study treatment or any other condition due to which individuals are deemed unsuitable by the investigator for reason(s) not specifically stated in the exclusion criteria
•9. Alcohol, smoke, and drug abusers will be excluded.

发起方

Multani Pharmaceuticals Ltd